MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Operating Income 2011-2026 | BIO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 269 M | 338 M | 483 M | 500 M | 421 M | 230 M | -103 M | 119 M | 55.7 M | 167 M | 150 M | 169 M | 264 M | 305 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 500 M | -103 M | 241 M |
Quarterly Operating Income Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.1 M | 23.7 M | 64.5 M | 102 M | 44.6 M | 90.9 M | 89.6 M | 61.9 M | - | 94.6 M | 123 M | 146 M | - | 157 M | 125 M | 101 M | - | 110 M | 51.7 M | 74.4 M | - | 57.5 M | 56.4 M | 56.6 M | - | 36.3 M | 43.8 M | 43.6 M | 45.9 M | 38.8 M | -1.7 M | 26.2 M | -28.2 M | 22.7 M | 26.9 M | 20.2 M | - | 32.7 M | 40.2 M | 34.3 M | - | 33.2 M | 45.7 M | 20.5 M | - | 29.1 M | 52.9 M | 35.2 M | - | 65.8 M | 73.3 M | 54.4 M | - | 73.9 M | 68.2 M | 67.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 157 M | -28.2 M | 58.9 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
AxoGen
AXGN
|
-3.29 M | $ 32.99 | 0.12 % | $ 1.46 B | USA |
 |
Abiomed
ABMD
|
230 M | - | - | $ 17.2 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 99.0 | 0.36 % | $ 146 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 9.57 | 0.31 % | $ 687 M |  Israel |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 22.72 | 3.41 % | $ 3.25 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.49 | 0.72 % | $ 121 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 28.83 | -1.08 % | $ 244 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 52.05 | -1.81 % | $ 7.76 K | USA |
 |
CONMED Corporation
CNMD
|
200 M | $ 44.57 | 2.65 % | $ 1.37 B | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 126.3 | -0.58 % | $ 220 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.71 | -2.37 % | $ 138 M |  France |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 99.94 | 1.63 % | $ 1.27 B | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-35 M | $ 18.86 | 2.53 % | $ 435 M | USA |
|
LENSAR
LNSR
|
-10.7 M | $ 11.8 | 2.34 % | $ 136 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Orthofix Medical
OFIX
|
-84.6 M | $ 16.29 | 3.56 % | $ 621 M |  Curacao |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.29 | -8.66 % | $ 1.13 B | Israel |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.21 | 1.6 % | $ 19.5 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 170.77 | 2.37 % | $ 12.8 B | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.9 | 3.41 % | $ 92.5 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 15.28 | -0.07 % | $ 413 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.56 | 0.08 % | $ 122 M | USA |
 |
Sintx Technologies
SINT
|
-13.4 M | $ 3.8 | -3.44 % | $ 14.2 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 94.68 | 4.58 % | $ 12.9 B | USA |
 |
LivaNova PLC
LIVN
|
129 M | $ 64.92 | 0.46 % | $ 3.52 B |  Britain |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 13.82 | 5.1 % | $ 1.06 B | USA |